- Conditions
- COPD (Chronic Obstructive Pulmonary Disease)
- Interventions
- Photon-counting CT, Energy-integrating CT
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- Not listed
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Sponsor Directory
Duke University clinical trials
Sponsor pages show live ClinicalTrials.gov search results and objective aggregate stats only. They do not describe sponsor quality, reputation, or expected outcomes.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
2714
Shown on this page
12
Current sort
Recently updated
Sponsor scope
Duke University
Additional filters apply within this sponsor.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 181–192 of 2,714 matching trials for sponsor Duke University.
Live ClinicalTrials.gov results.
Live official records
Open in full search- Conditions
- HIV Infections, Opioid Use Disorder, Incarceration; Lens
- Interventions
- Cabotegravir Injection, Cabotegravir Pill, Buprenorphine injection, Buprenorphine Pill
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 450 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Smoking Cessation, Pain
- Interventions
- Smoking cessation and pain management intervention, Varenicline
- Other · Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Stroke, Visual Field Defect, Visual Field Defect Following Cerebrovascular Accident, Hemianopia, Quadrantanopia, Occipital Lobe Infarct, Visual Fields Hemianopsia
- Interventions
- Low-intensity focused ultrasound, Immersive virtual reality, Inactive Low-intensity focused ultrasound
- Device
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Hyperpolarized 129 Xenon Gas Comparing Idiopathic Pulmonary Fibrosis (IPF) Treatment
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Alcohol Use Disorder (AUD), Major Depressive Disorder (MDD)
- Interventions
- Pregnenolone, Placebo
- Drug
- Lead sponsor
- Sherwood Brown, MD, PhD
- Other
- Eligibility
- 21 Years to 55 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 2
- States / cities
- Dallas, Texas • Richardson, Texas
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
- Interventions
- PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
- Biological · Drug
- Lead sponsor
- Nationwide Children's Hospital
- Other
- Eligibility
- 3 Years to 39 Years
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2030
- U.S. locations
- 13
- States / cities
- Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
- Conditions
- Low Grade Glioma of Brain
- Interventions
- PEPIDH1M vaccine + vorasidenib
- Drug
- Lead sponsor
- Katy Peters, MD, PhD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Prenatal; Postnatal
- Interventions
- Navigation Intervention Version 1.0 (discontinued, modified to Version 2.0. Data will not be used), Control Intervention, Navigation Intervention Version 2.0
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years and older
- Enrollment
- 815 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pelvic Organ Prolapse (POP), Cystocele, Pelvic Floor Disorder
- Interventions
- Poly-L-Lactic Acid (Sculptra) injection, Placebo injection (sterile water)
- Device · Other
- Lead sponsor
- Cassandra Kisby
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
- Interventions
- The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 0 Years to 20 Years
- Enrollment
- 5,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2026
- U.S. locations
- 49
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
- Conditions
- mCRPC (Metastatic Castration-resistant Prostate Cancer), Prostate Cancer
- Interventions
- Pocenbrodib, Pocenbrodib and Darolutamide
- Drug
- Lead sponsor
- Pathos AI, Inc.
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 19
- States / cities
- Fountain Valley, California • Los Alamitos, California • Aurora, Colorado + 16 more
About this Duke University sponsor directory page
- What this page lists
- U.S. ClinicalTrials.gov public records where Duke University is the lead sponsor, including recruiting, not yet recruiting, and active not recruiting trials across phase 1, phase 2, and phase 3.
- How to narrow results
- Use the filters above to scope by condition, intervention, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, age, or NCT ID within Duke University trials.
- Where the data comes from
- Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
- What this page does not do
- No medical advice, eligibility judgments, sponsor quality scoring, ranking of trials, or AI-generated medical summaries.
Related: all sponsor pages, browse by condition, browse by drug or therapy, browse by U.S. city, trials at Duke University Medical Center in Durham, NC, or open the full search for Duke University.